Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery.


Journal

HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921

Informations de publication

Date de publication:
02 2022
Historique:
received: 24 03 2021
revised: 10 05 2021
accepted: 21 06 2021
pubmed: 10 8 2021
medline: 6 4 2022
entrez: 9 8 2021
Statut: ppublish

Résumé

Loco-regional treatments have improved the survival of patients with early hepatocellular carcinoma (HCC), but tumor relapse is a frequent event and survival rates remain low. Moreover, conflicting evidences address early HCC patients to surgery or radiofrequency ablation (RFA), with the clinical need to find predictive non-invasive biomarkers able to guide treatment choice and define patients survival. Two independent case series of treatment-naïve HCC patients treated with local RFA, and a cohort of 30 HCC patients treated with liver surgery were enrolled. On the basis of literature evidence, we customized a panel of 21 miRNAs correlated with relapse and prognosis after local curative treatment of HCC. Expression levels of let-7c predict tumor relapse after RFA; we also investigated the same panel in a small cohort of HCC patients undergoing surgery, finding no statistically significance in predicting tumor relapse or survival. Moreover, interaction test indicated that let-7c expression levels are predictive for identifying a subset of patients that should be addressed to surgery. Results from this study could predict prognosis of early HCC patients, helping to address early HCC patients to surgery or RFA treatment.

Sections du résumé

BACKGROUND
Loco-regional treatments have improved the survival of patients with early hepatocellular carcinoma (HCC), but tumor relapse is a frequent event and survival rates remain low. Moreover, conflicting evidences address early HCC patients to surgery or radiofrequency ablation (RFA), with the clinical need to find predictive non-invasive biomarkers able to guide treatment choice and define patients survival.
METHODS
Two independent case series of treatment-naïve HCC patients treated with local RFA, and a cohort of 30 HCC patients treated with liver surgery were enrolled. On the basis of literature evidence, we customized a panel of 21 miRNAs correlated with relapse and prognosis after local curative treatment of HCC.
RESULTS
Expression levels of let-7c predict tumor relapse after RFA; we also investigated the same panel in a small cohort of HCC patients undergoing surgery, finding no statistically significance in predicting tumor relapse or survival. Moreover, interaction test indicated that let-7c expression levels are predictive for identifying a subset of patients that should be addressed to surgery.
CONCLUSION
Results from this study could predict prognosis of early HCC patients, helping to address early HCC patients to surgery or RFA treatment.

Identifiants

pubmed: 34366240
pii: S1365-182X(21)00603-1
doi: 10.1016/j.hpb.2021.06.421
pii:
doi:

Substances chimiques

Circulating MicroRNA 0
MicroRNAs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

244-254

Informations de copyright

Copyright © 2021 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Auteurs

Matteo Canale (M)

Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy.

Francesco Giuseppe Foschi (FG)

Department of Internal Medicine, Ospedale per gli Infermi of Faenza, Faenza, Italy.

Pietro Andreone (P)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche Materno Infantili e dell'Adulto (SMECHIMAI), University of Modena and Reggio Emilia, Modena, Italy.

Giorgio Ercolani (G)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Department of General and Oncologic Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.

Giorgia Marisi (G)

Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy.

Fabio Conti (F)

Department of Internal Medicine, Ospedale per gli Infermi of Faenza, Faenza, Italy.

Ranka Vukotic (R)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Valeria Guarneri (V)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Valentina Burgio (V)

Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Milan, Italy.

Francesca Ratti (F)

Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy.

Luca Aldrighetti (L)

Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Francesco De Cobelli (F)

Vita-Salute San Raffaele University, Milan, Italy; Department of Radiology, IRCCS San Raffaele Hospital, Milan, Italy.

Stefano Cascinu (S)

Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Paola Ulivi (P)

Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy.

Andrea Casadei-Gardini (A)

Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: casadeigardini@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH